


Edited by Jörg Knäblein

 WILEY-VCH

Modern Biopharmaceuticals


Design, Development and Optimization

Volume 2



included

Dedicated to Francis Crick (1916–2004)



Modern Biopharmaceuticals

Volume 2

Design, Development and Optimization

Edited by
Jörg Knäblein



WILEY-VCH Verlag GmbH & Co. KGaA

Editor

Dr. Jörg Knäblein

Head Microbiological Chemistry
Schering AG
Müllerstraße 178
13342 Berlin
Germany

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.:

applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Bibliographic information published by

Die Deutsche Bibliothek

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>.

© 2005 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany

Printed on acid-free paper

Cover Tim Fonseca, www.fonsecatim.com

Typsetting K+V Fotosatz GmbH, Beerfelden

Printing betz-druck GmbH, Darmstadt

Bookbinding J. Schäffer GmbH, Grünstadt

ISBN-13 978-3-527-31184-2

ISBN-10 3-527-31184-X

Jörg Knäblein (Ed.)

Modern Biopharmaceuticals

Further Titles of Interest

Gary Walsh

Biopharmaceuticals
Biochemistry and Biotechnology

2003
ISBN 0-470-84326-8

Oliver Kayser, Rainer H. Müller (Eds.)

Pharmaceutical Biotechnology
Drug Discovery and Clinical Applications

2004
ISBN 3-527-30554-8

Gary Walsh

Proteins
Biochemistry and Biotechnology

2001
ISBN 0-471-89907-0

Rainer Fischer, Stefan Schillberg (Eds.)

Molecular Farming
Plant-made Pharmaceuticals and Technical Proteins

2004
ISBN 3-527-30786-9

Rodney J. Y. Ho, Milo Gibaldi

Biotechnology
and Biopharmaceuticals
Transforming Proteins and Genes into Drugs

2003
ISBN 0-471-20690-3

Martin Schleef (Ed.)

DNA-Pharmaceuticals
Formulation and Delivery in Gene Therapy
and DNA Vaccination

2005
ISBN 3-527-31187-4

Chi-Huey Wong (Ed.)

Carbohydrate-based
Drug Discovery

2003
ISBN 3-527-30632-3

Rolf D. Schmid, Ruth Hammelehle

Pocket Guide to Biotechnology
and Genetic Engineering

2003
ISBN 3-527-30895-4

Contents

Volume 1

Prologue XXV

Dedication XXIX

Foreword XXXI

Foreword XXXV

Quotes XXXVII

Executive Summary XLI

List of Contributors CXXIII

Introduction

Current Status of Biopharmaceuticals: Approved Products and Trends in Approvals 1
Gary Walsh

Part I Biopharmaceuticals Used in Molecular Medicine

From Genome to Clinic – Correlation Between Genes, Diseases and Biopharmaceuticals 37

1 Beginning to Understand the End of the Chromosome 37
Thomas R. Cech

**2 The Role of Pharmacogenetics/Pharmacogenomics
in Drug Development and Regulatory Review: Current Status** 49
Shiew-Mei Huang and Lawrence J. Lesko

- 3 **Large-scale Detection of Genetic Variation: The Key to Personalized Medicine** 71
 Joerg Geistlinger and Peter Ahnert

- 4 **A Systems Biology Approach to Target Identification and Validation
 for Human Chronic Disease Drug Discovery** 99
 Bonnie E. Gould Rothberg, Carol E.A. Peña, and Jonathan M. Rothberg

- 5 **The Development of Herceptin®:
 Paving the Way for Individualized Cancer Therapy** 127
 Thorsten S. Gutmehr and Carsten Reinhardt

siRNA – the Magic Bullet and Other Gene Therapeutical Approaches 151

- 6 **Adenovirus-based Gene Therapy: Therapeutic Angiogenesis
 with Adenovirus 5 Fibroblast Growth Factor-4 (Ad5FGF-4) in Patients
 with Chronic Myocardial Ischemia** 151
 *Michael McCaman, Francisco J. Castillo, Farah Fawaz, Yasushi Ogawa, Erik Whiteley,
 Elisabeth Lehmerberg, Mei Tan, Jacob Kung, Bruce Mann, Erno Pungor Jr.,
 and Gabor M. Rubanyi*

- 7 **MIDGE Vectors and dSLIM Immunomodulators:
 DNA-based Molecules for Gene Therapeutic Strategies** 183
 Manuel Schmidt, Barbara Volz, and Burghardt Wittig

- 8 **Nonprotein-coding RNAs and their Potential as Biopharmaceuticals** 213
 Maciej Szymanski, Jan Barciszewski and Volker A. Erdmann

- 9 **Double-stranded Decoy Oligonucleotides as new Biopharmaceuticals** 229
 Andreas H. Wagner and Heiko E. von der Leyen

- 10 **Rational siRNA Design for RNA Interference:
 Optimizations for Therapeutic Use and Current Applications** 243
 Anastasia Khvorova, Queta Boese, and William S. Marshall

Mobilis in Mobile – Human Embryonic Stem Cells and Other Sources for Cell Therapy 269

- 11 **The First Cloned Human Embryo: An Unlimited Source of Stem Cells
 for Therapeutic Cloning** 269
 Woo Suk Hwang, Byeong Chun Lee, Sung Keun Kang, and Shin Yong Moon

- 12 **Myocardial Regeneration Strategies using Human Embryonic Stem Cells** 283
 Izhak Kehat, Oren Caspi, and Lior Gepstein

- 13 **Gene and Cell-based Therapies for Cardiovascular Disease** 305
 Abeel A. Mangi

- 14 **Spheramine®: A Cell Therapeutic Approach to Parkinson's Disease** 325
Elke Reissig, Hermann Graf, and Friedrich-Joachim Kapp
- 15 **Applying Human Cells to Organogenesis and Transplantation** 353
Benjamin Dekel and Yair Reisner

Volume 2

Part II Biopharmaceuticals and Their Mode of Action

Quid pro Quo – Lysis vs. Coagulation in the Fine-tuned Balance of the Clotting Cascade 377

- 1 **Mechanisms of Serine Proteinase Activation: Insights for the Development of Biopharmaceuticals for Coagulation and Fibrinolysis** 377
Rainer Friedrich
- 1.1 Introduction 378
- 1.2 Bacterial Activators of Host Zymogens 381
- 1.3 Some Remarks on Nonproteolytic Activators 388
- 2 **Application of the Principle of Polyvalency to Protease Inhibition** 395
Luis Moroder
- 2.1 Introduction 395
- 2.2 Thermodynamic Model of Bivalent Ligand Binding 396
- 2.3 Homo- and Heterobivalent Inhibitors of the Yeast 20S Proteasome 398
- 2.4 Bivalent Inhibition of Mast Cell β -Tryptase 405
- 2.5 Heterobivalent Inhibition of Thrombin 411
- 2.6 Perspectives 414
- 3 **A New Technology Standard for Safety and Efficacy in Factor VIII Replacement Therapy: Designing an Advanced Category rFVIII Concentrate** 419
Norbert Riedel and Friedrich Dorner
- 3.1 Introduction 420
- 3.2 Development of rFVIII 428
- 3.3 Production of rFVIII 430
- 3.4 Pathogen Safety 433
- 3.5 Quality Control 435
- 3.6 Purity and Potency 435
- 3.7 Preclinical Studies 436
- 3.8 Clinical Studies 439
- 3.9 Summary 447

Errare Humanum Est – What Causes Cancer and How to Selectively Fight Tumors 451**4 Biopharmaceutical Drugs from Natural Sources 451***David J. Newman, Gordon M. Cragg, and Barry R. O'Keefe*

4.1 Biotechnologically Produced Proteins and Peptides as Approved Drugs 452

4.2 Potential Agents from Non-mammalian Sources as Leads
to Novel Therapies 481

4.3 Overall Concluding Comments 488

**5 Biopharmaceuticals as Targeting Vehicles for *In situ* Radiotherapy
of Malignancies 497***Raymond M. Reilly*

5.1 Introduction 498

5.2 Principles of Targeted *In situ* Radiotherapy of Malignancies 499

5.3 RIT of Non-Hodgkin's B-Cell Lymphomas: The Pre-eminent Success Story 500

5.4 Other Strategies for *In situ* Radiotherapy of Non-Hodgkin's Lymphoma 505

5.5 Radioimmunotherapy of AML: Success but not Cure 505

5.6 RIT of Solid Tumors: Encouraging Results in Minimal Residual Disease 507

5.7 Pre-Targeting Strategies: Improving the Therapeutic Index of RIT 511

5.8 Peptide-Directed *In situ* Radiotherapy: Targeting Somatostatin Receptors 516

5.9 Auger Electron Radiotherapy: Anti-tumor Effects at the Single Cell Level 519

5.10 α -Particle RIT: Anti-tumor Effects at the Multi-cell Level 525

5.11 Conclusion 526

**6 New Directions in Tumor Therapy –
Amino Acid Depletion with GlutaDON® as Treatment for Cancer 537***Rolf Kalhammer and Natarajan Sethuraman*

6.1 Rationale for GlutaDON® Therapy 537

6.2 Preclinical Studies 539

6.3 PEGylation and Protection from Inactivation 541

6.4 Toxicology 545

6.5 Clinical Trial 545

6.6 Summary and Conclusions 546

Mundus Vult Decipi – High Mutation Rates of HIV and New Paradigms for Treatment 549**7 AIDS Gene Therapy: A Vector Selectively Able to Destroy Latently HIV-1-infected
Cells 549***Francisco Luque Vázquez and Ricardo Oya*

7.1 The Genes and Life Cycle of HIV-1 551

7.2 Gene Therapy of AIDS 553

7.3 Viral Latency: the Real Challenge 557

7.4 A Vector Able Selectively to Destroy Latently Infected Cells 559

8 Combinatorial RNA-based Therapies for HIV-1 569*Kevin V. Morris and John J. Rossi*

- 8.1 Introduction 569
- 8.2 RNA-based Antiviral Agents 570
- 8.3 RNAi: Diversity of Viral Targets 571
- 8.4 Delivery of siRNAs to Target Cells 573
- 8.5 Challenges for RNA-based Therapies 577
- 8.6 Summary and Conclusion 577

Part III Improving the Development of Biopharmaceuticals**Citius, Altius, Fortius – Acceleration by High Throughput and Ultra-HT 583****1 Design of Modern Biopharmaceuticals by Ultra-high-throughput Screening and Directed Evolution 583***Markus Rarbach, Wayne M. Coco, Andre Koltermann, Ulrich Kettling, and Manfred Eigen*

- 1.1 Modern Biopharmaceuticals 584
- 1.2 Directed Evolution Fundamentals 585
- 1.3 Generation of Protein Diversity 586
- 1.4 Selection Strategies 593
- 1.5 High-throughput and High-content Screening of Protein Libraries 594
- 1.6 Directed Evolution of Biopharmaceuticals 598
- 1.7 Conclusions 601

2 Learning from Viruses: High-throughput Cloning using the Gateway® System to Transfer Genes without Restriction Enzymes 605*Jonathan D. Chesnut*

- 2.1 Introduction 605
- 2.2 Background 606
- 2.3 Engineering the Lambda System to Create Gateway 609
- 2.4 The Gateway Reactions 610
- 2.5 Creating Gateway Entry Clones 611
- 2.6 Gateway Destination Vectors 613
- 2.7 Applications Enabled by Gateway Cloning 614
- 2.8 HTP Expression Analysis in Mammalian Cells 614
- 2.9 HTP Cloning and Expression in a Baculovirus System 615
- 2.10 Multisite Gateway 616
- 2.11 Creation of Entry Vectors and Three-fragment Multisite Assembly Reaction 618
- 2.12 Perspective 621

In Vivo Veritas – Early Target Validation in Knock-out Mice and More 621

- 3 Target Validation: An Important Early Step in the Development of Novel Biopharmaceuticals in the Post-genomic Era 621**
Christoph P. Bagowski
 - 3.1 Introduction 622
 - 3.2 RNA- and DNA-based Techniques for Post-transcriptional Regulation of Molecular Targets, and their Potential as Biopharmaceutical Drugs 624
 - 3.3 Peptide and Protein-based Approaches 636
 - 3.4 Protein Kinases as Targets for Drug Development 639
 - 3.5 Cell-based Assays for *In vitro* Target Validation in the Drug Discovery Process 640
 - 3.6 Animal Models as the Ultimate Target Validation 645
 - 3.7 Summary and Conclusions 645
- 4 Genetically Modified Mice in Medical and Pharmaceutical Research 649**
Cord Brakebusch
 - 4.1 Disease-oriented Research in Genetically Modified Mice 649
 - 4.2 Generation of Genetically Modified Mice by Gene Targeting 651
 - 4.3 Analysis of Genetically Modified Mice 659
 - 4.4 Alternative Methods 659
- 5 An NIH Model Organism for Biopharmaceutical and Biomedical Research: The Lower Eukaryote *Dictyostelium discoideum* 661**
Thomas Winckler, Ilse Zündorf, and Theodor Dingermann
 - 5.1 Introduction 664
 - 5.2 The Gene Discovery Tool Box or *Dictyostelium* Research 665
 - 5.3 Production of Recombinant Proteins in *D. discoideum* 672
 - 5.4 *Dictyostelium discoideum* in Biomedical Research 685
 - 5.5 Conclusions 689

Revolution by Evolution – Rational Design for Desire and Scientific Art of Optimization 695

- 6 Releasing the Spring: Cofactor- and Substrate-assisted Activation of Factor IXa 695**
Hans Brandstetter and Katrin Sichler
 - 6.1 Introduction 695
 - 6.2 The Zymogen Form of fIX is Fully Inactive 697
 - 6.3 Relevance of Tyr99 on the Stability of the 99-loop 697
 - 6.4 Lys98 Hinders Substrate Binding to fIXa both Sterically and Electrostatically 698
 - 6.5 Tyr177 Locks the 99-loop in an Inactive Conformation, which is Released by Cofactor fVIIIa and Modified by the Physiologic Substrate fX 699
 - 6.6 S1 Site Mutations Decrease the Activity of fIXa 699
 - 6.7 Evolutionary Relation of fIXa and fXa is Reflected in the Dependence of Activity Changes on Arg/Lys Substrates 700

- 6.8 By Binding at the 60-loop Ethylene Glycol Indirectly Reorganizes the 99-loop and Allosterically Stimulates the Activity of fIXa 700
- 6.9 Summary and Conclusion 701
- 7 Accelerating Diagnostic Product Development Process with Molecular Rational Design and Directed Evolution 703**
Harald Sobek, Rainer Schmuck, and Zhixin Shao
 - 7.1 Introduction 704
 - 7.2 Strategies for Optimizing Diagnostic Proteins 705
 - 7.3 Examples 709
 - 7.4 Summary 717

Volume 3

Part IV Production of Biopharmaceuticals

The Industry's Workhorses – Mammalian Expression Systems 723

- 1 Manufacture of Recombinant Biopharmaceutical Proteins by Cultivated Mammalian Cells in Bioreactors 723**
Florian M. Wurm
- 2 Alternative Strategies and New Cell Lines for High-level Production of Biopharmaceuticals 761**
Thomas Rose, Karsten Winkler, Elisabeth Brundke, Ingo Jordan and Volker Sandig
- 3 PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins 779**
Chris Yallop, John Crowley, Johanne Cote, Kirsten Hegmans-Brouwer, Fija Lagerwerf, Rodney Gagne, Jose Coco Martin, Nico Oosterhuis, Dirk-Jan Opstelten, and Abraham Bout
- 4 Use of the Glutamine Synthetase (GS) Expression System for the Rapid Development of Highly Productive Mammalian Cell Processes 809**
John R. Birch, David O. Mainwaring, and Andrew J. Racher

Vivat, Crescat, Floreat – A Ripe and Blooming Market for Transgenic Animals and Plants 833

- 5 Biopharmaceuticals Derived from Transgenic Plants and Animals 833**
Julio Baez
- 6 Production of Recombinant Proteins in Plants 893**
Victor Klimyuk, Sylvestre Marillonnet, Jörg Knäblein, Michael McCaman, and Yuri Gleba

- 7 **Humanized Glycosylation: Production of Biopharmaceuticals
in a Moss Bioreactor** 919
Gilbert Gorr and Sabrina Wagner

- 8 **ExpressTec: High-level Expression of Biopharmaceuticals in Cereal Grains** 931
Ning Huang and Daichang Yang

- 9 **Biopharmaceutical Production in Cultured Plant Cells** 949
Stefan Schillberg, Richard M. Twyman, and Rainer Fischer

- 10 **Producing Biopharmaceuticals in the Desert: Building an Abiotic Stress Tolerance
in Plants for Salt, Heat, and Drought** 967
Shimon Gepstein, Anil Grover, and Eduardo Blumwald

- 11 **The First Biopharmaceutical from Transgenic Animals: ATryn®** 995
Yann Echelard, Harry M. Meade, and Carol A. Ziomek

- Alea Non lacta Est – Improving Established Expression Systems** 1021

- 12 **Producing Modern Biopharmaceuticals: The Bayer HealthCare Pharma Experience
with a Range of Expression Systems** 1021
Heiner Apeler

- 13 **Advanced Expression of Biopharmaceuticals in Yeast at Industrial Scale:
The Insulin Success Story** 1033
Asser Sloth Andersen and Ivan Diers

- 14 **Baculovirus-based Production of Biopharmaceuticals using Insect Cell Culture
Processes** 1045
Wilfried Weber and Martin Fussenegger

- 15 **Robust and Cost-effective Cell-free Expression of Biopharmaceuticals:
Escherichia Coli and Wheat Embryo** 1063
Luke Anthony Miles

- When Success Raises its Ugly Head – Outsourcing to Uncork the Capacity Bottleneck** 1083

- 16 **Contract Manufacturing of Biopharmaceuticals Including Antibodies
or Antibody Fragments** 1083
J. Carsten Hempel and Philipp N. Hess

Part V Biopharmaceuticals used for Diagnostics and Imaging

From Hunter to Craftsman – Engineering Antibodies with Nature's Universal Toolbox 1105

- 1 **Thirty Years of Monoclonal Antibodies:
A Long Way to Pharmaceutical and Commercial Success** 1105
Uwe Gottschalk and Kirsten Mundt
- 2 **Modern Antibody Technology: The Impact on Drug Development** 1147
Simon Moroney and Andreas Plückthun
- 3 **Molecular Characterization of Autoantibody Responses in Autoimmune Diseases:
Implications for Diagnosis and Understanding of Autoimmunity** 1187
Constanze Breithaupt

Find, Fight, and Follow – Target-specific Troika from Mother Nature's Pharmacopoeia 1211

- 4 **Molecular Imaging and Applications for Pharmaceutical R&D** 1211
Joke G. Orsel and Tobias Schaeffter
- 5 **Design and Development of Probes for *In vivo* Molecular and Functional Imaging
of Cancer and Cancer Therapies by Positron Emission Tomography (PET)** 1243
Eric O. Aboagye
- 6 **Ligand-based Targeting of Disease:
From Antibodies to Small Organic (Synthetic) Ligands** 1271
Michela Silacci and Dario Neri
- 7 **Ultrasound Theranostics: Antibody-based Microbubble Conjugates as Targeted *In vivo*
Contrast Agents and Advanced Drug Delivery Systems** 1301
Andreas Briel, Michael Reinhardt, Mathias Mäurer, and Peter Hauff

Getting Insight – Sense the Urgency for Early Diagnostics 1325

- 8 **Development of Multi-marker-based Diagnostic Assays with the ProteinChip®
System** 1325
Andreas Wiesner
- 9 **Early Detection of Lung Cancer: Metabolic Profiling of Human Breath with Ion Mobility
Spectrometers** 1343
Jörg Ingo Baumbach, Wolfgang Vautz, Vera Ruzsanyi, and Lutz Freitag

Volume 4

Part VI Advanced Application Routes for Biopharmaceuticals

Getting Inside – Quest for the Best and How to Improve Delivery 1361

- 1 **Advanced Drug Delivery Systems for Biopharmaceuticals** 1361
Gesine E. Hildebrand and Stephan Harnisch

Pathfinder – New Ways for Peptides, Proteins and Co 1393

- 2 **Poly(ethylene) Glycol Conjugates of Biopharmaceuticals in Drug Delivery** 1393
Michael D. Bentley, Mary J. Bossard, Kevin W. Burton, and Tacey X. Viegas
- 3 **Novel Vaccine Adjuvants Based on Cationic Peptide Delivery Systems** 1419
Karen Lingnau, Christoph Klade, Michael Buschle, and Alexander von Gabain
- 4 **The Evolving Role of OralTM (Oral Spray Insulin) in the Treatment of Diabetes using a Novel RapidMistTM Diabetes Management System** 1445
Pankaj Modi
- 5 **Improvement of Intestinal Absorption of Peptide and Protein Biopharmaceuticals by Various Approaches** 1463
Akira Yamamoto

Via Mala – the Stoney Road of DNA Delivery: Back-pack, Feed-back, and Pay-back 1487

- 6 **DNA Vaccine Delivery from Poly(ortho ester) Microspheres** 1487
Chun Wang, Herman N. Eisen, Robert Langer, and Jorge Heller
- 7 **Liposomal *In vivo* Gene Delivery** 1507
Shigeru Kawakami, Fumiyoshi Yamashita, and Mitsuru Hashida
- 8 **Programmed Packaging:
A New Drug Delivery System and its Application to Gene Therapy** 1521
Kentaro Kogure, Hidetaka Akita, Hiroyuki Kamiya, and Hideyoshi Harashima

Getting Beyond – Rocket Science vs. Science Fiction 1537

- 9 **Bionanotechnology and its Role to Improve Biopharmaceuticals** 1537
Oliver Kayser

Part VII From Transcription to Prescription of Biopharmaceuticals

Dosis Facit Venenum – The Therapeutic Window between Systemic Toxicity and Lack of Efficacy 1557

- 1 **Analytics in Quality Control and *In vivo*** 1557
Michael Hildebrand
- 2 **Design, Development and Optimization: Crystal Structures of Microsomal Cytochromes P450** 1581
Dijana Matak Vinković, Sheena Whyte, Harren Jhoti, Jose Cosme, and Pamela A. Williams
- 3 **Mettox™: A Suite of Predictive *In silico* and *In vitro* Assays for Metabolic and Genotoxicological Profiling of Preclinical Drug Candidates** 1603
Michael Murray

Happy End: Claim to Fame and Approval 1637

- 4 **Considerations for Developing Biopharmaceuticals: FDA Perspective** 1637
Kurt Brorson, Patrick G. Swann, Janice Brown, Barbara Wilcox, and Marjorie A. Shapiro
- 5 **The Regulatory Environment for Biopharmaceuticals in the EU** 1669
Axel F. Wenzel and Carina E. A. Sonnegå

Part VIII From Bench to Bedside – The Aftermaths

Think Big and Dealmaking for Growth – Global Changes in the Health-care Sector 1711

- 1 **Healthcare Trends and their Impact on the Biopharmaceutical Industry: Biopharmaceuticals Come of Age** 1711
Alexander Moscho, Markus A. Schäfer, and Kristin Yarema

News and Views – Quo Vadis, Biopharmaceuticals? 1741

- 2 **mondoBIOTECH: The Swiss biotech BOUTIQUE** 1741
Dorian Bevec and Fabio Cavalli
- 3 **G-CSF and Bioequivalence: The Emergence of Healthcare Economics** 1755
James Harris, III

Light at the End of the Tunnel or Back to the Roots? 1771

4 Bioinformatics: From Peptides to Profiled Leads 1771

Paul Wrede and Matthias Filter

5 Engineering and Overproduction of Polyketide Natural Products 1803

Martha Lovato Tse and Chaitan Khoslat

Epilog 1833

More about the Editor 1835

Supplement CD-ROM 1837

Subject Index 1841